Navigation Links
AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
Date:4/9/2013

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

"We ultimately envision this as a prognostic tool to predict survival rates for people with tobacco related cancers. Recognizing patients with high expression of these genes could help us predict risk and so match patients with the most appropriate treatments," says Garrett Dancik, PhD, postdoc in the lab of Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center.

The study mined data from publicly-available tumor registries that included a total of 1996 samples of cancer types including lung adenocarcinoma, squamous cell lung carcinoma, bladder transitional cell carcinoma, and head and neck squamous cell carcinoma. The question was this: what common genetic signatures would correlate with patient outcomes? Interestingly, researchers had previously asked this question of prostate cancer and had developed a panel of 31 cell-cycle related genes that predict the aggressiveness of the disease. Once Dancik and Theodorescu narrowed in on pathways controlling cell cycle as possibly predictive in tobacco-related cancers, they wondered if the same 31-gene panel might work with these cancers as well.

"Take out the squamous cell cancers and the panel is strongly predictive of patient outcomes," Dancik says. "This is a strong tool that could have a really useful application only it seems there's something unique going on with the squamous cell types of tobacco-associated cancers that's not true for the others."

In Dancik's opinion, the discovery of correlation between cell cycle gene signatures and patient outcomes is an important first step in developing new ways to predict the risks of tobacco-associated cancers. The work now is in integrating this finding with existing risk assessments.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. AACR news: New target plus new drug equals death of melanoma cells
7. AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
8. Fruit fly studies guide investigators to misregulated mechanism in human cancers
9. Planarian genes that control stem cell biology identified
10. Culprit behind unchecked angiogenesis identified
11. Researchers identify genes that may help in ovarian cancer diagnosis and prognosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... ... , ... FireflySci, Inc is an explosive small business that continues to grow ... bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy world. ... on as they add yet another mark on the global map. , With distributors ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
Breaking Biology Technology: